Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)

NCT01900197 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 391

Last updated 2016-03-02

No results posted yet for this study

Summary

The purpose of this study is to monitor and quality assure the efficacy and safety of Monofer® in a broad patient population when Monofer® is used according to the Monofer® label (SPC) in current practice and where standard routines are being followed.

Conditions

Interventions

DRUG

10% Iron Isomaltoside 1000

Administered according to local routines and product labeling in doses at the doctors discretion

Sponsors & Collaborators

  • BioStata

    collaborator INDUSTRY
  • Pharmacosmos A/S

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01900197 on ClinicalTrials.gov